{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T03:04:27Z","timestamp":1791255867939,"version":"4.1.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2013,11,22]],"date-time":"2013-11-22T00:00:00Z","timestamp":1385078400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2014,2]]},"DOI":"10.1007\/s10147-013-0641-7","type":"journal-article","created":{"date-parts":[[2013,11,21]],"date-time":"2013-11-21T01:19:15Z","timestamp":1384996755000},"page":"3-9","source":"Crossref","is-referenced-by-count":28,"title":["Ever-advancing chronic myeloid leukemia treatment"],"prefix":"10.1007","volume":"19","author":[{"given":"Shinya","family":"Kimura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshihiko","family":"Ando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kensuke","family":"Kojima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,11,22]]},"reference":[{"key":"641_CR1","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1056\/NEJM200104053441401","volume":"344","author":"BJ Druker","year":"2001","unstructured":"Druker BJ, Talpaz M, Resta DJ et al (2001) Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 344:1031\u20131037","journal-title":"N Engl J Med"},{"key":"641_CR2","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa022457","volume":"348","author":"SG O\u2019Brien","year":"2003","unstructured":"O\u2019Brien SG, Guilhot F, Larson RA et al (2003) Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 348:994\u20131104","journal-title":"N Engl J Med"},{"key":"641_CR3","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","volume":"122","author":"M Baccarani","year":"2013","unstructured":"Baccarani M, Deininger MW, Rosti G et al (2013) European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood 122:872\u2013884","journal-title":"Blood"},{"key":"641_CR4","unstructured":"O\u2019Brien S, Abboud CN, Akhtari M et al (2012) NCCN Clinical Practice Guidelines in Oncology: Chronic Myelogenous Leukemia. Version 2, 2013. Available at: NCCN.org. Accessed Sep 17, 2012"},{"key":"641_CR5","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1182\/blood.V114.22.462.462","volume":"114","author":"M Deininger","year":"2009","unstructured":"Deininger M, O\u2019Brien SG, Guilhot F et al (2009) International randomized study of Interferon vs STI571 (IRIS) 8-year follow up: Sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib. Blood 114:462 (Abstract 1126)","journal-title":"Blood"},{"key":"641_CR6","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1126\/science.1062538","volume":"293","author":"ME Gorre","year":"2001","unstructured":"Gorre ME, Mohammed M, Ellwood K et al (2001) Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 293:876\u2013880","journal-title":"Science"},{"key":"641_CR7","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/S0925-4439(02)00095-9","volume":"1587","author":"T Hegedus","year":"2002","unstructured":"Hegedus T, Orfi L, Seprodi A et al (2002) Interaction of tyrosine kinase inhibitors with the human multidrug transporter proteins, MDR1 and MRP1. Biochim Biophys Acta 1587:318\u2013325","journal-title":"Biochim Biophys Acta"},{"key":"641_CR8","doi-asserted-by":"crossref","first-page":"3821","DOI":"10.1182\/blood-2007-08-109330","volume":"111","author":"J Wu","year":"2008","unstructured":"Wu J, Meng F, Lu H et al (2008) Lyn regulates BCR-ABL and Gab2 tyrosine phosphorylation and c-Cbl protein stability in imatinib resistant chronic myelogenous leukemia cells. Blood 111:3821\u20133829","journal-title":"Blood"},{"key":"641_CR9","doi-asserted-by":"crossref","first-page":"2761","DOI":"10.1200\/JCO.2009.26.5819","volume":"28","author":"DL White","year":"2010","unstructured":"White DL, Dang P, Engler J et al (2010) Functional activity of the OCT-1 protein is predictive of long-term outcome in patients with chronic-phase chronic myeloid leukemia treated with imatinib. J Clin Oncol 28:2761\u20132767","journal-title":"J Clin Oncol"},{"key":"641_CR10","doi-asserted-by":"crossref","first-page":"14907","DOI":"10.1073\/pnas.0606176103","volume":"103","author":"J Kuroda","year":"2006","unstructured":"Kuroda J, Puthalakath H, Cragg MS et al (2006) Bim and Bad mediate imatinib-induced killing of Bcr\/Abl+ leukemic cells, and resistance due to their loss is overcome by a BH3 mimetic. Proc Natl Acad Sci USA 103:14907\u201314912","journal-title":"Proc Natl Acad Sci USA"},{"key":"641_CR11","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/nm.2713","volume":"18","author":"KP Ng","year":"2012","unstructured":"Ng KP, Hillmer AM, Chuah CT et al (2012) A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer. Nat Med 18:521\u2013528","journal-title":"Nat Med"},{"key":"641_CR12","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.canlet.2011.08.009","volume":"312","author":"R Tanaka","year":"2011","unstructured":"Tanaka R, Kimura S, Ashihara E et al (2011) Rapid automated detection of ABL kinase domain mutations in imatinib-resistant patients. Cancer Lett 312:228\u2013234","journal-title":"Cancer Lett"},{"key":"641_CR13","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1182\/blood-2012-05-431379","volume":"121","author":"JS Khorashad","year":"2013","unstructured":"Khorashad JS, Kelley TW, Szankasi P et al (2013) BCR-ABL1 compound mutations in tyrosine kinase inhibitor-resistant CML: frequency and clonal relationships. Blood 121:489\u2013498","journal-title":"Blood"},{"key":"641_CR14","doi-asserted-by":"crossref","first-page":"3278","DOI":"10.1182\/blood-2008-10-183665","volume":"116","author":"DW Sherbenou","year":"2010","unstructured":"Sherbenou DW, Hantschel O, Kaupe I et al (2010) BCR-ABL SH3-SH2 domain mutations in chronic myeloid leukemia patients on imatinib. Blood 116:3278\u20133285","journal-title":"Blood"},{"key":"641_CR15","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1126\/science.1099480","volume":"305","author":"NP Shah","year":"2004","unstructured":"Shah NP, Tran C, Lee FY et al (2004) Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 305:399\u2013401","journal-title":"Science"},{"key":"641_CR16","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1016\/j.leukres.2007.11.008","volume":"32","author":"Y Deguchi","year":"2008","unstructured":"Deguchi Y, Kimura S, Ashihara E et al (2008) Comparison of imatinib, dasatinib, nilotinib and INNO-406 in imatinib-resistant cell lines. Leuk Res 32:980\u2013983","journal-title":"Leuk Res"},{"key":"641_CR17","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1038\/leu.2008.84","volume":"22","author":"A Hochhaus","year":"2008","unstructured":"Hochhaus A, Baccarani M, Deininger M et al (2008) Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib. Leukemia 22:1200\u20131206","journal-title":"Leukemia"},{"key":"641_CR18","doi-asserted-by":"crossref","first-page":"3204","DOI":"10.1200\/JCO.2007.14.9260","volume":"26","author":"NP Shah","year":"2008","unstructured":"Shah NP, Kantarjian HM, Kim DW et al (2008) Intermittent target inhibition with dasatinib 100\u00a0mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia. J Clin Oncol 26:3204\u20133212","journal-title":"J Clin Oncol"},{"key":"641_CR19","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1056\/NEJMoa1002315","volume":"362","author":"H Kantarjian","year":"2010","unstructured":"Kantarjian H, Shah NP, Hochhaus A et al (2010) Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 362:2260\u20132270","journal-title":"N Engl J Med"},{"key":"641_CR20","doi-asserted-by":"crossref","first-page":"135","DOI":"10.3324\/haematol.13151","volume":"94","author":"DH Kim","year":"2009","unstructured":"Kim DH, Kamel-Reid S, Chang H et al (2009) Natural killer or natural killer\/T cell lineage large granular lymphocytosis associated with dasatinib therapy for Philadelphia chromosome positive leukemia. Haematologica 94:135\u2013139","journal-title":"Haematologica"},{"key":"641_CR21","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ccr.2005.01.007","volume":"7","author":"E Weisberg","year":"2005","unstructured":"Weisberg E, Manley PW, Breitenstein W et al (2005) Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell 7:129\u2013141","journal-title":"Cancer Cell"},{"key":"641_CR22","doi-asserted-by":"crossref","first-page":"3540","DOI":"10.1182\/blood-2007-03-080689","volume":"110","author":"HM Kantarjian","year":"2007","unstructured":"Kantarjian HM, Giles F, Gattermann N et al (2007) Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood 110:3540\u20133546","journal-title":"Blood"},{"key":"641_CR23","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","volume":"362","author":"G Saglio","year":"2010","unstructured":"Saglio G, Kim DW, Issaragrisil S et al (2010) Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 362:2251\u20132259","journal-title":"N Engl J Med"},{"key":"641_CR24","first-page":"375","volume":"3","author":"JM Golas","year":"2003","unstructured":"Golas JM, Arndt K, Etienne D et al (2003) SKI-606, a 4-anilino-3-quinolinecarbonitrile dual inhibitor of Src and Abl kinases, is a potent antiproliferative agent against chronic myelogenous leukemia cells in culture and causes regression of K562 xenografts in nude mice. Cancer Res 3:375\u2013381","journal-title":"Cancer Res"},{"key":"641_CR25","doi-asserted-by":"crossref","first-page":"3948","DOI":"10.1182\/blood-2005-06-2209","volume":"106","author":"S Kimura","year":"2005","unstructured":"Kimura S, Naito H, Segawa H et al (2005) NS-187, a potent and selective dual Bcr-Abl\/Lyn tyrosine kinase inhibitor, is a novel agent for imatinib-resistant leukemia. Blood 106:3948\u20133954","journal-title":"Blood"},{"key":"641_CR26","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.1002\/cncr.25079","volume":"16","author":"H Kantarjian","year":"2010","unstructured":"Kantarjian H, le Coutre P, Cortes J et al (2010) Phase I study of INNO-406, a dual Abl\/Lyn kinase inhibitor, in Philadelphia chromosome-positive leukemias post-imatinib resistance or intolerance. Cancer 16:2665\u20132672","journal-title":"Cancer"},{"key":"641_CR27","doi-asserted-by":"crossref","first-page":"e65129","DOI":"10.1371\/journal.pone.0065129","volume":"8","author":"SZ Imam","year":"2013","unstructured":"Imam SZ, Trickler W, Kimura S et al (2013) Neuroprotective efficacy of a new brain-penetrating C-Abl inhibitor in a murine Parkinson\u2019s disease model. PLoS One 8:e65129","journal-title":"PLoS One"},{"key":"641_CR28","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.ccr.2009.09.028","volume":"16","author":"T O\u2019Hare","year":"2009","unstructured":"O\u2019Hare T, Shakespeare WC, Zhu X et al (2009) AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell 16:401\u2013412","journal-title":"Cancer Cell"},{"key":"641_CR29","first-page":"116","volume":"2010","author":"S Kimura","year":"2010","unstructured":"Kimura S (2010) Second generation Abl kinase inhibitors and novel compounds to eliminate the Bcr-Abl\/T315I clone (Second Edition). Recent Pat Anticancer Drug Discov 2010:116\u2013131","journal-title":"Recent Pat Anticancer Drug Discov"},{"key":"641_CR30","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1182\/blood-2009-08-237115","volume":"115","author":"S Saussele","year":"2010","unstructured":"Saussele S, Lauseker M, Gratwohl A et al (2010) Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era: evaluation of its impact within a subgroup of the randomized German CML Study IV. Blood 115:1880\u20131885","journal-title":"Blood"},{"key":"641_CR31","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/S1470-2045(10)70233-3","volume":"11","author":"FX Mahon","year":"2010","unstructured":"Mahon FX, R\u00e9a D, Guilhot J et al (2010) Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2\u00a0years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol 11:1029\u20131035","journal-title":"Lancet Oncol"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-013-0641-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10147-013-0641-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-013-0641-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,20]],"date-time":"2024-05-20T04:06:38Z","timestamp":1716177998000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10147-013-0641-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,11,22]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,2]]}},"alternative-id":["641"],"URL":"https:\/\/doi.org\/10.1007\/s10147-013-0641-7","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,11,22]]}}}